Skip to content

ACADIA Pharmaceuticals

US · ACAD #2404 by market cap Listed 1970
17.11 -0.48 -2.73%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
  • Total institutional ownership rose 0.6 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
100.17% +0.60pp
Institutions
428 +1
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund52.60%
Hedge Fund40.63%
Public Company2.69%
Government Pension Fund1.14%
VC/PE Fund0.97%
Sovereign Wealth Fund0.96%
Individual/Insider0.55%
Private Company0.55%
Insurance Company0.54%
Other0.60%

Top holders as of 2026-06-30

Baker Bros. Advisors LP 24.83% · 42.91M sh
BlackRock 13.28% · 22.95M sh
Vanguard Portfolio Management, LLC 5.47% · 9.46M sh
State Street Global Advisors 4.43% · 7.65M sh
RTW Investments, LP 4.13% · 7.14M sh
Vanguard Capital Management, LLC 3.35% · 5.79M sh
Geode Capital Management, LLC 1.95% · 3.37M sh
Dimensional Fund Advisors 1.95% · 3.37M sh
Palo Alto Investors LP 1.66% · 2.86M sh
Qube Research & Technologies Ltd 1.42% · 2.45M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 35 buys · 15 sells

NameRoleStake
Baker Bros. Advisors LP -- 24.83%
Stephen Davis Former Chief Executive Officer 0.26%
Julian Baker Independent Director 0.06%
Mark Schneyer Chief Financial Officer 0.04%
Daniel Soland Former Independent Director 0.03%
Edmund Harrigan Independent Director 0.02%
Elizabeth Garofalo Independent Director 0.02%
Adora Ndu Independent Director 0.02%
Laura Brege Independent Director 0.01%
Elizabeth H. Thompson Former Head of Research & Development 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-29 Mark Schneyer Chief Financial Officer Automatic Disposition -3,321 $20.88
2026-10-14 Mark Schneyer Chief Financial Officer Other Acquisition +6,815 --
2026-08-05 Mark Schneyer Chief Financial Officer Derivative Exercise and Sale -20,141 $17.84–29.34
2026-08-04 Mark Schneyer Chief Financial Officer Intent to Sell (Form 144) -5,849 $27.15
2026-07-29 Elizabeth H. Thompson Former Head of Research & Development Derivative Exercise and Sale -16,558 $26.13–26.17
2026-07-28 Elizabeth H. Thompson Former Head of Research & Development Derivative Exercise and Retained +15,714 --
2026-06-25 James Kihara Officer Automatic Disposition -11,421 $26.08
2026-05-28 Laura Brege Independent Director Other Derivative Acquisition +9,311 --
2026-05-28 Laura Brege Independent Director Other Derivative Acquisition +16,004 $21.66
2026-05-28 Laura Brege Independent Director Derivative Exercise and Retained +8,107 --
2026-05-28 Julian Baker Independent Director Other Derivative Acquisition +64,016 $21.66
2026-05-28 Edmund Harrigan Independent Director Other Derivative Acquisition +9,311 --
2026-05-28 Edmund Harrigan Independent Director Other Derivative Acquisition +16,004 $21.66
2026-05-28 Edmund Harrigan Independent Director Derivative Exercise and Retained +8,107 --
2026-05-28 James Daly Independent Director Other Derivative Acquisition +9,311 --
2026-05-28 James Daly Independent Director Other Derivative Acquisition +16,004 $21.66
2026-05-28 James Daly Independent Director Derivative Exercise and Retained +8,107 --
2026-05-28 Baker Bros. Advisors LP -- Other Acquisition +37,244 --
2026-05-28 Jonathan Poole Independent Director Other Derivative Acquisition +9,311 --
2026-05-28 Jonathan Poole Independent Director Other Derivative Acquisition +16,004 $21.66

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

ACADIA Pharmaceuticals discussion 0 comments

Add a comment